Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Directa Plus Plc (DTPKF)
Lomazzo, CO, IT
Directa Plus Plc is an Italian company, founded in 2003 and headquartered in Lomazzo, which focuses on developing and commercializing graphene-based products. These advanced materials are designed for a broad spectrum of industrial and commercial uses, serving clients in Italy and worldwide. The firm organizes its business activities into distinct segments, including Textile, Environmental, and other divisions. Its proprietary products are uniformly branded as G+. The versatile applications of Directa Plus's materials span across environmental solutions, elastomers, textiles, composite fabrication, and a variety of finished goods such as golf balls, footwear, and tyres.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -89.58% | -77.78% | -71.43% | -75.00% | -97.78% | -98.75% | -98.18% | -98.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Chemicals - Specialty: +4.7%-36.7% Q2'25: -15.0% (vs Q2'23)
-
EPS growth Chemicals - Specialty: +13.2%-32.7% Q2'25: +27.0% (vs Q2'23)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%-46.6% Q2'25: -35.3% (vs Q2'23)
-
EBIT margin Chemicals - Specialty: +8.8%-78.2% Q2'25: -39.5% (vs Q2'23)
-
ROIC Chemicals - Specialty: +5.6%-115.8% Q2'25: -139.6% (vs Q2'23)
-
Share dilution Chemicals - Specialty: +0.1%+0.4% Q2'25: +56.3% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×-0.58× Q2'25: -0.43× (vs Q2'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. |
Dec 2027 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
740.7K
est: 1.16M (-36.2%)
|
1.04M
est: 1.08M (-4.1%)
|
2.25M
est: 2.69M (-16.1%)
|
2.63M
est: 3.37M (-21.8%)
|
6.43M
est: 6.73M (-4.4%)
|
8.62M
est: 9.55M (-9.8%)
|
10.86M
est: 11.13M (-2.5%)
|
10.53M
est: 12.14M (-13.3%)
|
6.66M
est: 6.70M (-0.6%)
|
7.00M
est.
|
41.96M
41.96M – 41.96M
+499.6% YoY
|
57.00M
57.00M – 57.00M
+35.8% YoY
|
| EBITDA |
-3.90M
est: -471.7K (-727.1%)
|
-3.29M
est: -439.4K (-647.9%)
|
-3.26M
est: -1.09M (-198.3%)
|
-3.12M
est: -1.37M (-127.6%)
|
-2.89M
est: -2.74M (-5.6%)
|
-3.09M
est: -3.88M (+20.4%)
|
-3.81M
est: -4.53M (+15.8%)
|
-2.84M
est: -4.94M (+42.4%)
|
-4.03M
est: -2.72M (-47.8%)
|
-2.84M
est.
|
-17.06M
-17.06M – -17.06M
-499.6% YoY
|
-23.17M
-23.17M – -23.17M
-35.8% YoY
|
| EBIT |
-6.21M
est: -660.3K (-840.2%)
|
-3.92M
est: -615.1K (-537.3%)
|
-3.93M
est: -1.53M (-157.2%)
|
-3.39M
est: -1.92M (-76.9%)
|
-4.58M
est: -3.83M (-19.6%)
|
-4.14M
est: -5.43M (+23.8%)
|
-5.21M
est: -6.33M (+17.7%)
|
-4.11M
est: -6.91M (+40.5%)
|
-5.21M
est: -3.81M (-36.7%)
|
-3.98M
est.
|
-23.88M
-23.88M – -23.88M
-499.6% YoY
|
-32.44M
-32.44M – -32.44M
-35.8% YoY
|
| Net Income |
-6.42M
est: -10.35M (+38.0%)
|
-3.95M
est: -6.42M (+38.5%)
|
-3.96M
est: -5.29M (+25.1%)
|
-3.59M
est: -4.48M (+19.9%)
|
-4.20M
est: -4.98M (+15.7%)
|
-3.65M
est: -3.31M (-10.4%)
|
-4.82M
est: -4.22M (-14.3%)
|
-3.86M
est: -3.88M (+0.5%)
|
-5.14M
est: -3.84M (-34.0%)
|
-2.22M
est.
|
—
— – —
+100.0% YoY
|
—
— – —
|
| SGA |
1.93M
est: 363.2K (+432.1%)
|
2.42M
est: 338.3K (+615.2%)
|
2.12M
est: 841.0K (+152.1%)
|
—
est: 1.05M (-100.0%)
|
3.81M
est: 2.11M (+80.7%)
|
1.85M
est: 2.99M (-38.0%)
|
1.96M
est: 3.48M (-43.8%)
|
1.88M
est: 3.80M (-50.5%)
|
2.66M
est: 2.10M (+26.8%)
|
2.19M
est.
|
13.14M
13.14M – 13.14M
+499.6% YoY
|
17.84M
17.84M – 17.84M
+35.8% YoY
|
| EPS |
-0.19
est: -0.15 (-23.6%)
|
-0.09
est: -0.10 (+5.7%)
|
-0.09
est: -0.08 (-13.7%)
|
-0.07
est: -0.07 (-5.3%)
|
-0.07
est: -0.07 (+7.0%)
|
-0.06
est: -0.05 (-21.1%)
|
-0.07
est: -0.06 (-16.5%)
|
-0.06
est: -0.06 (-4.2%)
|
-0.08
est: -0.06 (-45.8%)
|
-0.03
est.
|
—
— – —
+100.0% YoY
|
—
— – —
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Giulio Giuseppe Cesareo | Founder, CEO & Interim Chairman | 465.9K | male |
| Giorgio Bonfanti | Chief Financial Officer | 233.5K | male |
| Alessandra Bambini | Sales & Marketing Director | — | female |
| Razvan Popescu | Chief Operating Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DTPKF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
